estudos artísticos

O tropicalismo arranca em 1967, através do corpo: a música de Caetano Veloso e Gilberto Gil, os vestíveis de Hélio Oiticica, as propostas teatrais de José Celso Martinez Corrêa e os cenários de Hélio Eichbauer. Hoje as coisas são um pouco mais complexas. Em tempo de redes sociais, os aspirantes ao poder fazem uso da sua imediatez para suscitarem reações epidérmicas, superficiais, populistas e de grande instantaneidade. A boçalidade triunfa nas caixas de comentários, e com mais alguns perfis falsificados podem manipular-se plebiscitos, movimentos secessionistas, ou, e também censurar-se exposições de arte. Nesta variação do fascismo, a epiderme eletrificada das redes sociais estrutura-se como uma poderosa arena onde se aparenta uma falsa democracia. Talvez a arte continue a ser um reduto para reflexão, mas vemos que a censura se manifesta hoje de modo talvez mais eficaz, silenciando artistas e professores, através da pressão mediatizada, da emoção do momento. Para isto é necessária a atenção consciente da arte, dos artistas, e também dos arte-educadores: enfrenta-se uma massa cada vez mais informe, alienada e despojada de reflexão para além do imediato.info:eu-repo/semantics/publishedVersio

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension

Neapolitan crib of Sacred Art Museum of San Paulo and other international collections : set design and expography

Orientador: Luciano MigliaccioTese (doutorado) - Universidade Estadual de Campinas, Instituto de Filosofia e Ciências HumanasResumo: A pesquisa partiu da análise documental do Presépio Napolitano pertencente ao Museu de Arte Sacra de São para estudar as questões cenográficas envolvidas nesta tipologia presepial. Inicialmente, foi realizada uma revisão dos aspectos abordados na dissertação de mestrado intitulada Presépio Napolitano do Museu de Arte Sacra de São Paulo: percurso metodológico para a elaboração de um inventário científico, a qual contribuiu para o levantamento histórico da criação do Museu dos Presépios em São Paulo. A partir da problemática da exibição dos núcleos presepiais, a tese revisa a bibliografia sobre a tradição napolitana e se ocupa das questões cenográficas dos conjuntos napolitanos, de seus personagens característicos e de seus grupos cênicos para discutir as mudanças de gosto expográfico ao longo dos séculos. Ademais, o estudo abarca comparações de soluções cênicas entre os núcleos napolitanos e outras tipologias presepiais, bem como as soluções expografia nos diversos centros mundiais que possuem coleções napolitanas. Assim, uma das contribuições da tese é avaliação das condições atuais das cenografias existente nessas coloções e o levantamento das motivações de suas escolhas museográficasAbstract: Based on the analysis of the documents about the Neapolitan crib that belongs to Museu de Arte Sacra de São Paulo, the research intended to study the scenographic issues involved in this kind of crib collection. Initially, we performed a review of the issues discussed in the dissertation entitled Neapolitan Crib of the Museum of Sacred Art in São Paulo: methodological approach for the development of a scientific survey, which contributed to record the historical aspects of the creation of the Museu dos Presépios in São Paulo. From the matter of the crib's collections displaying, the thesis reviews the literature on the Neapolitan, their typical figures and its scenic groups to discuss the exhibition changes throughout the centuries. Moreover, the study includes comparisons among Neapolitan crib's scenic solutions and other crib's type, as well as expography solutions from others centers that have Neapolitan collections around the world. Thus, one of the contributions of the thesis is evaluating the sceneries conditions of the current collections and the motivation of their museographic choicesDoutoradoHistoria da ArteDoutor em Históri

Preservação do Presepio Napolitano do Museu de Arte Sacra de São Paulo : percursos metodologicos para a elaboração de um inventario cientifico

Orientador: Luciano MigliaccioDissertação (mestrado) - Universidade Estadual de Campinas, Instituto de Filosofia e Ciencias HumanasResumo: A pesquisa partiu da análise documental do exemplar pertencente Museu de Arte Sacra de São Paulo para promover o resgate das informações históricas que permitissem o traçado de diretrizes para sua conservação e preservação. Para tanto, o estudo tratou da revisão da documentação existente junto ao museu, que até o momento não havia sido sistematizada e organizada. Dado o volume de elementos a serem tratados em conjunto, e com a finalidade de facilitar posteriores acessos à coleção, o acervo ganhou um banco de dados. Este reúne as informações existentes nos diversos tombamentos e nas fichas catalográficas, fornecendo subsídios sobre trocas de acessórios e problemas de conservação, por quê a coleção passou ao longo dos anos, além de contar com registros fotográficosAbstract: Based on the analyze of the documents about the Neapolitan crib that belongs to Museu de Arte Sacra de São Paulo, the research intended to put together its historical information to allow create policy for its conservation and preservation. To achieve it¿s proposed, during the study, all documents that exist in the museum was reviewed and organized. As lots of records must be treated together, and intending to improve access into the collection, it was designed one database to manage the collection. It puts together the information of the different inventory and cataloguing data, and offers elements of the change of the accessories, conservation problems and photographic recordsMestradoHistoria da ArteMestre em Históri

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

The terminal complement inhibitor eculizumab was shown to improve myasthenia gravis-related symptoms in the 26-week, phase 3, randomized, double-blind, placebo-controlled REGAIN study (NCT01997229). In this 52-week sub-analysis of the open-label extension of REGAIN (NCT02301624), eculizumab's efficacy and safety were assessed in 11 Japanese and 88 Caucasian patients with anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis. For patients who had received placebo during REGAIN, treatment with open-label eculizumab resulted in generally similar outcomes in the Japanese and Caucasian populations. Rapid improvements were maintained for 52 weeks, assessed by change in score from open-label extension baseline to week 52 (mean [standard error]) using the following scales (in Japanese and Caucasian patients, respectively): Myasthenia Gravis Activities of Daily Living (−2.4 [1.34] and − 3.3 [0.65]); Quantitative Myasthenia Gravis (−2.9 [1.98] and − 4.3 [0.79]); Myasthenia Gravis Composite (−4.5 [2.63] and − 4.9 [1.19]); and Myasthenia Gravis Quality of Life 15-item questionnaire (−8.6 [5.68] and − 6.5 [1.93]). Overall, the safety of eculizumab was consistent with its known safety profile. In this interim sub-analysis, the efficacy and safety of eculizumab in Japanese and Caucasian patients were generally similar, and consistent with the overall REGAIN population

Consistent improvement with eculizumab across muscle groups in myasthenia gravis

Objective: To assess whether eculizumab, a terminal complement inhibitor, improves patient- and physician-reported outcomes (evaluated using the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale, respectively) in patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis across four domains, representing ocular, bulbar, respiratory, and limb/gross motor muscle groups. Methods: Patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis were randomized 1:1 to receive either placebo or eculizumab during the REGAIN study (NCT01997229). Patients who completed REGAIN were eligible to continue into the open-label extension trial (NCT02301624) for up to 4 years. The four domain scores of each of the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale recorded throughout REGAIN and through 130 weeks of the open-label extension were analyzed. Results: Of the 125 patients who participated in REGAIN, 117 enrolled in the open-label extension; 61 had received placebo and 56 had received eculizumab during REGAIN. Patients experienced rapid improvements in total scores and all four domain scores of both the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale with eculizumab treatment. These improvements were sustained through 130 weeks of the open-label extension. Interpretation: Eculizumab treatment elicits rapid and sustained improvements in muscle strength across ocular, bulbar, respiratory, and limb/gross motor muscle groups and in associated daily activities in patients with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis

Long-term safety and efficacy of eculizumab in generalized myasthenia gravis

Introduction: Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open-label extension of REGAIN, evaluating eculizumab's long-term safety and efficacy. Methods: Eculizumab (1,200 mg every 2 weeks for 22.7 months [median]) was administered to 117 patients. Results: The safety profile of eculizumab was consistent with REGAIN; no cases of meningococcal infection were reported during the interim analysis period. Myasthenia gravis exacerbation rate was reduced by 75% from the year before REGAIN (P < 0.0001). Improvements with eculizumab in activities of daily living, muscle strength, functional ability, and quality of life in REGAIN were maintained through 3 years; 56% of patients achieved minimal manifestations or pharmacological remission. Patients who had received placebo during REGAIN experienced rapid and sustained improvements during open-label eculizumab (P < 0.0001). Discussion: These findings provide evidence for the long-term safety and sustained efficacy of eculizumab for refractory gMG. Muscle Nerve 2019

Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis (Quality of Life Research, (2019), 28, 8, (2247-2254), 10.1007/s11136-019-02148-2)

The article “Eculizumab improves fatigue in refractory generalized myasthenia gravis”, written by “Henning Andersen, Renato Mantegazza, Jing Jing Wang, Fanny O’Brien, Kaushik Patra, James F. Howard Jr. and The REGAIN Study Group” was originally published electronically on the publisher’s internet portal (currently SpringerLink) on 23 March 2019 without open access